立体定向消融放疗治疗局部晚期非小细胞肺癌:系统综述与荟萃分析
该系统综述与荟萃分析纳入7项研究共268例不适合或拒绝同步放化疗的局部晚期非小细胞肺癌患者,评估原发灶及淋巴结立体定向消融放疗的可行性、疗效与安全性。汇总1年局部控制率为80%,1年与2年总生存率分别为74%和55%,3级急性毒性为5%,5级毒性为1.7%。作者认为结果有前景但需进一步研究验证。
要点
- 汇总1年局部控制率为80%(95%CI:63-94%)。
- 1年与2年总生存率分别为74%(95%CI:58-90%)和55%(95%CI:34-76%)。
- 3级急性毒性汇总率为5%(95%CI:1-10%),5级毒性为1.7%(95%CI:0-3%)。
核心结论
- 作者认为,对局部晚期非小细胞肺癌采用立体定向消融放疗的局部控制与总生存结果有前景且毒性有限(可行性),但需进一步研究,强调需要更大规模、设计良好的试验进一步验证该方法。
研究设计与样本
- 按照PRISMA与MOOSE指南开展系统综述与荟萃分析。
- 共纳入7项研究(3项前瞻性研究、4项回顾性研究),涉及268例接受原发灶及淋巴结立体定向消融放疗的患者。
- 排除评估立体定向体部放疗作为原发放疗后推量的研究。
- 主要结局为局部控制与总生存,次要终点为严重毒性(3-5级)发生率。
- 采用荟萃回归分析探索局部控制、总生存与严重毒性之间的关系,生物等效剂量(BED)作为连续变量分析,统计学显著性定义为p值<0.05。
主要发现
- 汇总1年局部控制率为80%(95%CI:63-94%)。
- 与局部控制显著相关的因素为BEDGy10(p=0.005)和新辅助化疗(p=0.005)。
- 1年与2年总生存率分别为74%(95%CI:58-90%)和55%(95%CI:34-76%)。
- 荟萃回归分析显示总生存与局部控制呈线性关系,局部控制每改善1%,总生存增加0.7%(p=0.005)。
- 3级急性毒性汇总率为5%(95%CI:1-10%),5级毒性发生率为1.7%(95%CI:0-3%)。
关键数值与推荐
- 纳入标准为评估局部晚期非小细胞肺癌患者接受立体定向消融放疗结局的报告。
- 排除标准为评估立体定向体部放疗作为原发放疗后推量的研究。
- 统计学显著性定义为p值<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出该结果需进一步研究,强调需要更大规模、设计良好的试验进一步验证该方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To evaluate the feasibility, efficacy and safety of stereotactic ablative radiotherapy (SABR) to the primary tumor and lymph nodes in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who are ineligible for or refused concomitant chemoradiation. MATERIALS AND METHODS: In accordance with the PRISMA and MOOSE guidelines, a systematic review with meta-analysis was conducted. The study included reports that assessed the outcomes of SABR treatment in patients with LA-NSCLC. Studies evaluating SBRT as a boost following primary radiotherapy were excluded. The primary outcomes measured were local control (LC) and overall survival (OS). The secondary endpoint was the incidence of severe toxicity (grades 3-5). A meta-regression analysis was performed to explore the relationship between LC, OS, and severe toxicity. The Biologically Effective Dose (BED) was analyzed as a continuous variable. Statistical significance was defined as a p-value < 0.05. RESULTS: A total of seven studies (3 prospective and 4 retrospective studies) involving 268 patients (SBRT to primary and lymph nodes) were included in the analysis. The pooled 1-year LC rate was 80 % (95 % CI: 63-94 %), and the factors significantly associated with LC were BEDGy10 (p = 0.005) and neoadjuvant chemotherapy (p = 0.005). The 1-year and 2-year OS rates were 74 % (95 % CI: 58-90 %) and 55 % (95 % CI: 34-76 %), respectively. Meta-regression analysis indicated a linear relationship between OS and LC, with a 0.7 % increase in OS for each 1 % improvement in LC (p = 0.005). The pooled rate of grade 3 acute toxicity was 5 % (95 % CI: 1-10 %), and the rate of grade 5 toxicity was 1.7 % (95 % CI: 0-3 %). CONCLUSION: Promising results (LC and OS) with limited toxicity (feasibility) using SABR in LA-NSCLC warrant further research, emphasizing the need for larger, well-designed trials for further validation of the approach.
引用
- Viani GA, Gouveia AG, Louie AV, et al. Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2024. PMID: 39032835. doi:10.1016/j.radonc.2024.110439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。